HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders.
More About HiFiBiO
Presenters: Ross Fulton, Jinping Gan, Yun-Yueh Lu, Julianna Crivello, Zachery Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Wenhua Xu, Xing Cai, Joyce Pi, Dean Lee, Monika Manne, Ruina Jin, Yuan Wang, Hongkai Zhang, Nicola Beltraminelli, Francisco Adrian, Robert Petit, Liang Schweizer, Andreas Raue HFB301001 is being developed … Continued
Presenters: Germain Margall, Muriel David, Julie Prigent, Dean Lee, Wenhua Xu, Joyce Pi, Xing Cai, Tengfei Wang, Ouyang Li, He Zhou, Andreas Raue, Nicola Beltraminelli, Mingjie Chen, Jia Wu, Mingfang Feng, Angelo Paci, Julia Delahousse, Véronique Saada, Stéphane de Botton, Pierre Busson, Stephanie Beq, Francisco Adrian, Liang Schweizer, Yun-Yueh Lu HFB2009 program focuses on developing … Continued
Presenters: Shuo Wei, Ross Fulton, Yun-Yueh Lu, Qian Zhang, He Zhou, Andreas Raue, Mingjie Chen, Wenhua Xu, Xing Cai, Juliana Crivello, Zachary Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Dean Lee, Monika Manne, Nicola Beltraminelli, Jinping Gan, Francisco Adrian, Liang Schweizer, Jennifer Watkins-Yoon HFB200301 is an anti-TNFR2 … Continued
Presenters: Ross Fulton, Jinping Gan, Yun-Yueh Lu, Julianna Crivello, Zachery Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Wenhua Xu, Xing Cai, Joyce Pi, Dean Lee, Monika Manne, Ruina Jin, Yuan Wang, Hongkai Zhang, Nicola Beltraminelli, Francisco Adrian, Robert Petit, Liang Schweizer, Andreas Raue HFB301001 is being developed … Continued
Drug Discovery and Development Expertise
Our scientific leadership team brings decades of drug R&D experiences at leading pharmaceutical companies, along with a proven track record of delivering multiple marketed immuno-oncology and oncology drugs, as well as clinical candidates. We understand what it takes to advance a full pipeline of novel antibody drugs to treat cancer, autoimmune disorders and other unmet medical needs around the world.
Transformational Single-Cell Platform
As a pioneer in ultra-high-throughput phenotyping and genotyping single-cell analysis, we are enabling a paradigm shift in biotherapeutic discovery and development efforts. Our proprietary antibody screening CelliGO™ system combines with our Drug Intelligent Science (DIS™) to enable rapid identification of differentiated therapeutic molecules and significantly enhance clinical probability of success.
Unique Immune Profiling Translational Focus
Building upon our internal proprietary translational capabilities for single cell immune profiling, we have engaged the world’s top clinical immunologists and oncologists to drive a clinical development strategy that better connects biological targets to patient characteristics. Our primary indication drivers are unmet medical needs and deep understanding of mechanisms of action.
Open-Innovation Strategy
We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to accelerate the development of novel R&D technology platforms and identification of innovative therapeutics to improve patient care. All of our collaborations are architected for speed and driven by our scientific strategy.
Dynamic and Sustainable Pipeline
We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types, initially focused on regulatory T cells and Myeloid-derived suppressor cells, to combat cancer and autoimmune disorders. Currently, we are advancing 10 internal R&D programs, majority first-in-class, toward the clinic with multiple preclinical candidates demonstrating proof of concept in animal models.
Our scientific leadership team brings decades of drug R&D experiences at leading pharmaceutical companies, along with a proven track record of delivering multiple marketed immuno-oncology and oncology drugs, as well as clinical candidates. We understand what it takes to advance a full pipeline of novel antibody drugs to treat cancer, autoimmune disorders and other unmet medical needs around the world.
As a pioneer in ultra-high-throughput phenotyping and genotyping single-cell analysis, we are enabling a paradigm shift in biotherapeutic discovery and development efforts. Our proprietary antibody screening CelliGO™ system combines with our Drug Intelligent Science (DIS™) to enable rapid identification of differentiated therapeutic molecules and significantly enhance clinical probability of success.
Building upon our internal proprietary translational capabilities for single cell immune profiling, we have engaged the world’s top clinical immunologists and oncologists to drive a clinical development strategy that better connects biological targets to patient characteristics. Our primary indication drivers are unmet medical needs and deep understanding of mechanisms of action.
We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to accelerate the development of novel R&D technology platforms and identification of innovative therapeutics to improve patient care. All of our collaborations are architected for speed and driven by our scientific strategy.
We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types, initially focused on regulatory T cells and Myeloid-derived suppressor cells, to combat cancer and autoimmune disorders. Currently, we are advancing 10 internal R&D programs, majority first-in-class, toward the clinic with multiple preclinical candidates demonstrating proof of concept in animal models.
